Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. by Robben, J.H. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
doi:10.1152/ajprenal.00247.2006
 292:F253-F260, 2007. First published 22 August 2006;Am J Physiol Renal Physiol
J. H. Robben, M. Sze, N. V. A. M. Knoers and P. M. T. Deen
therapy of nephrogenic diabetes insipidus
in MDCK cells by pharmacochaperones: relevance to 
Functional rescue of vasopressin V2 receptor mutants
You might find this additional info useful...
36 articles, 18 of which can be accessed free at:This article cites 
 http://ajprenal.physiology.org/content/292/1/F253.full.html#ref-list-1
9 other HighWire hosted articles, the first 5 are:This article has been cited by 
 
 [PDF] [Full Text] [Abstract]
, March 23, 2010; 107 (12): 5569-5574.PNAS
Rui Zhang, Li Chen, Sarn Jiralerspong, Ann Snowden, Steven Steinberg and Nancy Braverman
Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds
 
 [PDF] [Full Text] [Abstract]
, June 25, 2010; 285 (26): 19854-19864.J. Biol. Chem.
Alice Cavanaugh, Jennifer McKenna, Ann Stepanchick and Gerda E. Breitwieser
Checkpoint and Endoplasmic Reticulum Retention
Calcium-sensing Receptor Biosynthesis Includes a Cotranslational Conformational
 
 [PDF] [Full Text] [Abstract]
, December , 2010; 335 (3): 520-532.J Pharmacol Exp Ther
Farooqi, Kenneth J. Valenzano and Michel Bouvier
Patricia René, Christian Le Gouill, Irina D. Pogozheva, Gary Lee, Henry I. Mosberg, I. Sadaf
Early-Onset Obesity
Pharmacological Chaperones Restore Function to MC4R Mutants Responsible for Severe
 
 [PDF] [Full Text] [Abstract]
, January 13, 2012; 287 (3): 2099-2106.J. Biol. Chem.
Fujita, Takashi Igarashi, Takashi Sekine and Taroh Iiri
Kenichiro Miura, Noriyuki Takubo, Atsuko Iida, Norishi Ueda, Makiko Hashimoto, Toshiro 
Kazuhiro Takahashi, Noriko Makita, Katsunori Manaka, Masataka Hisano, Yuko Akioka,
Highlight Protean Agonism of V2R Antagonists
V2 Vasopressin Receptor (V2R) Mutations in Partial Nephrogenic Diabetes Insipidus
 
 [PDF] [Full Text] [Abstract]
, May 15, 2012; 302 (10): C1421-C1433.Am J Physiol Cell Physiol
Dennis Brown, Richard Bouley, Teodor G. P?unescu, Sylvie Breton and Hua A. J. Lu
cells
New insights into the dynamic regulation of water and acid-base balance by renal epithelial
including high resolution figures, can be found at:Updated information and services 
 http://ajprenal.physiology.org/content/292/1/F253.full.html
 can be found at:AJP - Renal Physiologyabout Additional material and information 
http://www.the-aps.org/publications/ajprenal
This information is current as of July 11, 2012.
 
American Physiological Society. ISSN: 1931-857X, ESSN: 1522-1466. Visit our website at http://www.the-aps.org/.
(monthly) by the American Physiological Society, 9650 Rockville Pike, Bethesda MD 20814-3991. Copyright © 2007 by the
respective cells and vasculature, as well as to the control of body fluid volume and composition. It is published 12 times a year 
 publishes original manuscripts on a broad range of subjects relating to the kidney, urinary tract, and theirAJP - Renal Physiology
 o
n
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Robben JH, Sze M, Knoers NV, Deen PM. Functional rescue of
vasopressin V2 receptor mutants in MDCK cells by pharmacochap-
erones: relevance to therapy of nephrogenic diabetes insipidus. Am J
Physiol Renal Physiol 292: F253–F260, 2007. First published August
22, 2006; doi:10.1152/ajprenal.00247.2006.—Intracellular retention
of a functional vasopressin V2 receptor (V2R) is a major cause of
congenital nephrogenic diabetes insipidus (NDI) and rescue of V2R
mutants by nonpeptide antagonists may restore their basolateral mem-
brane (BM) localization and function. However, the criteria for
efficient functional rescue of G protein-coupled receptor (GPCR)
mutants at clinically feasible antagonist concentrations are unknown.
We found that the four nonpeptide antagonists SR49059, OPC31260,
OPC41061, and SR121463B induced maturation and rescued the BM
expression of eight of nine different V2R mutants, stably expressed in
physiologically relevant polarized cells. The extent of maturation and
rescued BM expression correlated with the antagonists’ concentration
and affinity for the V2R. Displacement of the antagonists by AVP and
subsequent cAMP generation inversely correlated with the antago-
nists’ affinities for the V2R but is partially influenced by antagonist-
specific aspects. Despite limited increases in maturation and cell-
surface expression of V2R mutants, the low-affinity SR49059 opti-
mally induced functional rescue at high concentrations, due to its easy
displacement by vasopressin. At clinically feasible antagonist concen-
trations, however, only the high-affinity antagonists OPC31260 and
OPC41061 induced functional rescue, as at these concentrations the
extent of BM expression became limited. In conclusion, functional
rescue of mutant V2Rs at clinically feasible concentrations is most
effective with high-affinity antagonists. As OPC31260 and
OPC41061 are clinically safe, they are promising candidates to relieve
NDI. Moreover, as numerous other diseases are caused by endoplas-
mic reticulum-retained GPCRs for which cell-permeable antagonists
become available, our finding that high-affinity antagonists are supe-
rior is anticipated to be important for pharmacotherapy development
of these diseases.
Madin-Darby canine kidney cells; misfolding; antagonist; water trans-
port
THE SYNTHESIS, MATURATION, and routing of plasma membrane
proteins are extremely complex processes that require specific
interactions between many different intracellular components.
It is not surprising, therefore, that flaws in these processes are
responsible for many diseases, which are often caused by
mutations in genes encoding membrane proteins. In the last
two decades, numerous mutations have been identified in the
coding sequences of such genes, of which 50% are missense
mutations involving only one or a few nucleotides. For exam-
ple, in cystic fibrosis (CF), a severe disorder caused by muta-
tions in the cystic fibrosis transmembrane conductance regula-
tor (CFTR) gene, 300 unique missense mutations have been
described (http://www.genet.sickkids.on.ca/cftr/). Cell expres-
sion studies revealed that most of these mutations lead to fully
synthesized proteins that fail to pass the quality control mech-
anism of the endoplasmic reticulum (ER) as the protein is
misfolded (10). Based on this cellular fate, these gene defects
are so-called class II mutations, giving rise to “conformational
diseases” (8). Usually, ER retention of such proteins is fol-
lowed by their degradation by proteasomes (22).
As numerous studies revealed that ER-retained mutant pro-
teins are often functional, research of the last decade has
focused on the identification of compounds that can rescue the
cell surface expression of such proteins. In this respect, the
vasopressin type 2 receptor (V2R) is the prototypical protein,
as it was the first receptor for which the exciting discovery was
made that cell-permeable antagonists (CPAn, known as “phar-
macological chaperones,” “pharmacochaperones,” or “pharma-
coperones”) can promote cell surface trafficking of its ER-
retained mutants (18).
V2R mutations cause the X-linked form of nephrogenic
diabetes insipidus (NDI), a disorder in which patients are
unable to concentrate their urine in response to the antidiuretic
hormone arginine-vasopressin (AVP) (13). Morello and co-
workers (18) showed that pretreatment with the high-affinity
cell-permeable V2R antagonist SR121463A rescued the cell
surface expression of 8 of 15 ER-retained V2R mutants (res-
cued cell surface expression), which could subsequently be
activated by AVP (i.e., functional rescue). Since then, the
concept by which CPAns rescue V2R mutants has been the
subject of several studies (4, 31, 34). As indicated above, a
crucial aspect necessary for functional rescue, besides rescued
cell surface expression of the mutant, is displacement of the
V2R-bound antagonist by AVP to generate a cAMP response.
Likely based on this requirement, a V1 receptor CPAn,
SR49059, was recently tested for its ability to increase the
urine concentrating abilities in NDI patients (5). For three
patients encoding the partially ER-retained V2R-R137H mu-
tant, a significant urine volume reduction was obtained, thereby
providing the proof of principle of the disease-curing effect of
pharmacological chaperones in vivo. In patients encoding the
fully ER-retained mutants V2R-W164S and V2R-62–64,
however, SR49059 was less effective.
To be of clinical value, functional rescue of V2R mutants
should occur at low concentrations of antagonists and AVP and
should last as long as possible. At present, however, it is
unclear which features of CPAn are important to give the best
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functional rescue of V2R mutants under such conditions.
Moreover, as the V2R is expressed in the basolateral mem-
brane (BM) of renal principal cells, and proteins can traffic or
function differently in nonpolarized vs. polarized cells (17),
such studies are best performed in polarized renal epithelial
cells.
Recently, we generated Madin-Darby canine kidney
(MDCK) cells stably expressing V2R tagged with a green
fluorescent protein (GFP) (23). In these cells, V2R-GFP was
localized and regulated as can be anticipated to occur for V2R
in vivo. Moreover, we found that several V2R mutants in NDI
stably expressed in MDCK cells are ER retained (24). To
determine which CPAn is likely the optimal pharmacological
chaperone to relieve NDI in patients, we thoroughly tested a
V1 receptor antagonist, a medium-affinity V2R antagonist, and
two high-affinity V2R antagonists for their ability to rescue the
cell surface expression and activity of several V2R mutants.
MATERIALS AND METHODS
Pharmacological chaperones. The V2R antagonist SR121463B
(28) and the V1R antagonist SR49059 (29) were kindly supplied by C.
Serradeil-Le Gal (Sanofi Synthe´labo, Toulouse, France). The V2R
antagonists OPC31260 and OPC41061 (14, 35) were kindly provided
by Koji Komuro (Otsuka Pharmaceutical, Tokushima, Japan). All
compounds were dissolved in dimethylsulfoxide as 0.01 M stock
solutions and diluted in culture medium as indicated.
Expression constructs, cell culture, and transfection. Expression
constructs encoding the wild-type V2R or the NDI-causing mutants
-L44P, -I130F, -S167T, or -S167L fused at their COOH terminus to
enhanced GFP were as described elsewhere (24). MDCK type II cells,
which lack endogenous V2R expression, were kindly provided by Dr.
Alexander Oksche (FMP, Berlin, Germany). MDCK type II cells were
maintained in DMEM (Biowittaker, Verviers, Belgium) supplemented
with 5% fetal bovine serum (PAA Laboratories, Karlsruhe, Germany),
gentamicin, L-glutamine, sodium carbonate, and 1% nonessential
amino acids. Calcium phosphate transfection and isolation of clones
were done as described for MDCK type I cells (9).
Immunoblotting and immunocytochemistry. Polyacrylamide gel
electrophoresis, Western blotting, and immunodetection were per-
formed as described elsewhere (9, 23). For detection of V2R-GFP,
1:5,000 diluted rabbit anti-GFP serum was used (kindly provided by
Prof. B. Wieringa, RUN-MC, Nijmegen, The Netherlands). As sec-
ondary antibodies, horseradish peroxidase-coupled goat anti-rabbit
IgGs (Sigma) were used. Immunocytochemistry, confocal laser-scan-
ning microscopy (CLSM), and data quantification were performed as
described elsewhere (24). As primary antibodies, 1:100-diluted rat
anti-E-cadherin (Sigma, St. Louis, MO) or rabbit anti-protein disulfide
isomerase antibodies (kindly provided by Dr. I. Braakman, Utrecht
University, Utrecht, The Netherlands) were used. As secondary anti-
bodies, 1:100-diluted goat anti-rat IgG or goat anti-rabbit IgG, both
coupled to Alexa 594, were used (Molecular Probes, Leiden, The
Netherlands).
[3H]AVP competition assay. Cells were seeded on 12 multiwell
filters (Costar) at a density of 150,000 cells/cm2 and grown for 3 days.
Cells were subsequently treated with the antagonists for 16 h, fol-
lowed by three washes with ice-cold phosphate-buffered saline con-
taining 1 mM MgCl2 and 0.1 mM CaCl2 (PBS-CM). The cells were
then incubated for 1 h on ice with [3H]AVP (PerkinElmer Life
Sciences, Boston, MA) and the antagonist diluted in PBS-CM. Cells
were washed three times with ice-cold PBS-CM, followed by excision
of the filters and counting of the radioactivity as described elsewhere
(23). Triplicate samples were measured, and every experiment was
performed at least in triplicate.
cAMP measurements. MDCK II cells were seeded on 24 multiwell
filters at a density of 150,000 cells/cm2, grown to confluence, and
treated with the antagonists as indicated. Subsequently, cells were
briefly washed in PBS-CM, followed by incubation for 10 min in
culture medium supplemented with 250 M IBMX (Sigma) to pre-
vent cAMP degradation by phosphodiesterases. Cells were then chal-
lenged for 10 min with DDAVP on the basolateral side in the presence
of IBMX. After three washing steps with PBS-CM, cells were lysed
in 100 l of 0.1 M HCl, and cAMP was measured using a fluorescent
cAMP assay kit (Sigma) according to the manufacturer’s protocol.
Triplicate samples were measured, and experiments were performed
at least in triplicate.
Statisical method and analysis. The statistical method used was
Student’s t-test. Averaged data of more than three independent exper-
iments are shown, and error bars represent SD. Statistical analysis was
performed using Microsoft Excel software.
RESULTS
Maturation of V2R mutants on antagonist treatment. During
folding in the ER, V2R is expressed in its high-mannose
glycosylated form. As it traverses the Golgi compartment on its
way to the BM, it matures to complex- and O-glycosylated
proteins. We have previously shown that missense V2R-GFP
proteins in NDI that are trapped in the ER (class II) do not
undergo maturation and are therefore visible as immature
proteins of 60–63 kDa when expressed in MDCK I cells (24).
Type I cells, however, endogenously express low levels of
V2R and are thus not suitable for functional testing of mutant
receptors. As MDCK II cells lack V2Rs (20), we stably
expressed wild-type (wt) V2R, the functional mutants V2R-
L44P, -I130F, and -S167T, and the nonfunctional V2R-S167L
in these cells. As found for MDCK I cells, wt-V2R was mainly
Fig. 1. Maturation of mutant V2 receptor (V2R) on antagonist treatment is
compound and mutation specific. Madin-Darby canine kidney (MDCK) II cells
expressing either wild-type (wt)-V2R, V2R-L44P, -I130F, -S167T, or -S167L
fused to green fluorescent protein (GFP) were seeded on filters and grown to
confluence, after which they were treated for 16 h with 1 M of indicated
cell-permeable V2R antagonists. Untreated cells (Untr.) were used as a control
(indicated). Cells were lysed and subsequently analyzed by SDS-PAGE fol-
lowed by immunoblotting using anti-GFP antibodies. Molecular masses (in
kDa) are indicated on the left.
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expressed in the mature 75-kDa form, while the missense
mutants were present as immature proteins of 60–63 kDa (Fig.
1, untreated samples). In addition, wt-V2R was mainly ex-
pressed in the BM, whereas the mutants were trapped in the ER
(Fig. 2, untreated cells).
As maturation can serve as a read-out for translocation of
mutant receptors to the BM, the cell-permeable antagonists
were tested for their ability to induce receptor maturation. As
shown in Fig. 1, overnight treatment with 1 M V1R antago-
nist SR4(9059) or the V2R antagonists OPC3(1260),
OPC4(1061), and SR1(21463) did not significantly (P  0.05)
increase the 75-kDa signal of wt-V2R. Treatment with OPC4
and SR1, however, caused a decrease or complete disappear-
ance of the 60-kDa signals, respectively, suggesting that these
compounds somewhat stabilize and increase receptor matura-
tion of wt-V2R. Treatment of MDCK cells expressing V2R-
L44P, -I130F, or -S167T (Fig. 1, middle 3 panels) with the four
compounds resulted in increased maturation of all receptor
mutants. However, the extent of maturation differed, as less
matured V2R proteins were observed with SR4 compared with
the other compounds. Moreover, especially for SR1, increased
receptor maturation was accompanied by a decrease in the
60-kDa signal. Maturation of V2R-S167L, the nonfunctional
mutant, was not increased by treatment with any of the com-
pounds tested, although its expression was somewhat increased
with SR1 (Fig. 1, bottom). In MDCK type I cells, similar
effects on maturation for the four compounds were observed
for V2R-L44P, -62–64, -R113W, -I130F, -G201D, -T204N
(not shown), and V2R-S167T and -V206D (26).
Rescue of V2R mutant plasma membrane expression on
antagonist treatment. To determine whether increased recep-
tor maturation coincided with increased BM localization,
the cells were also subjected to CLSM analysis. As reported
for MDCK type I cells (23), wt-V2R was predominantly
present in the BM of untreated MDCK II cells. Its localiza-
tion was not affected by treatment with any of the com-
pounds (Fig. 2, top row). Without treatment, V2R-L44P,
-I130F, -S167T, and -S167L were retained in the ER (Fig. 2
for V2R-L44P, -S167L), where they colocalized with the ER
marker protein disulfide isomerase.
Treatment for 16 h with 1 M SR4 did not visibly change
the localization of V2R-L44P (Fig. 2, middle row). Treatment
with OPC3, OPC4, or SR1, however, resulted in a clear
translocation of V2R-L44P to the BM (Fig. 2, middle row),
after which the localization was similar to that of wt-V2R.
V2R-I130F and -S167T proteins responded similarly to the
antagonist treatments as -L44P (not shown). V2R-S167L, how-
ever, did not translocate to the BM on antagonist treatment but
remained trapped in the ER (Fig. 2, bottom row). The lack of
a visible translocation of the V2R mutants by SR4, whereas
maturation was clearly observed (Fig. 1), indicates that CLSM
is less sensitive than immunoblotting.
Functional rescue of V2R mutants on antagonist treatment.
Following rescue to the plasma membrane, the antagonists
need to be displaced by an agonist to have functional rescue.
To study the rate of displacement, we used radioactively
labeled AVP, as this most closely resembles the natural ligand
of the V2R. When untreated, the amount of [3H]AVP bound by
mock-transfected cells was low compared with wtV2R-ex-
pressing cells (Fig. 3A). Also, [3H]AVP binding to untreated
MDCK II cells expressing V2R-L44P, -I130F, -S167T, or
-S167L was not significantly (P 0.05) different from binding
to mock-transfected cells. To further exclude the presence of
endogenous V2R in these cells, or the presence of low levels of
V2R mutants in the plasma membrane, we determined whether
DDAVP induces cAMP generation in these cell lines. How-
ever, treatment of mock-transfected MDCK II cells with 100
nM DDAVP did not result in a cAMP response, whereas cells
stably expressing wt-V2R showed an 10-fold increase in
intracellular cAMP levels compared with untreated cells. Also,
the cell lines expressing the mutants V2R-L44P, -I130F,
-S167T, and -S167L did not respond to DDAVP treatment. In
addition, basal cAMP levels were not significantly different
between all cell lines and clones tested. Together, these data
Fig. 2. Selective restoration of the plasma
membrane expression of V2R-L44P by phar-
macological chaperones. MDCK II cells ex-
pressing wt-V2R, V2R-L44P, or V2R-
S167L (indicated) were seeded, grown, and
treated for 16 h with 1 M of indicated
cell-permeable V2R antagonists. Untreated
cells were used as a control (indicated). Cells
were fixed, subjected to immunocytochemis-
try to stain for the endoplasmic reticulum
(ER) marker protein disulfide isomerase
(PDI; indicated in red), and analyzed by
confocal laser-scanning microscopy. V2R-
GFP is indicated in green.
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reveal that without rescued cell surface expression of V2R
mutants, these cells lack the ability to bind AVP or generate
cAMP in response to DDAVP.
This was different with rescued cell surface expression.
Pretreatment of MDCK-V2R cells with 1 M SR4 did not
interfere with binding of AVP at all, as a similar amount of
AVP was bound as found for nonpretreated control MDCK-
V2R cells (Fig. 4A). In contrast, both OPC3 and OPC4 treat-
ment reduced the amount of available binding sites for the
wild-type receptor to 30% of the nonpretreated control
MDCK-V2R cells, indicating that both compounds are dis-
placed by AVP to some extent. Finally, pretreatment with SR1
decreased the amount of available wt-V2R binding sites by
95% compared with control cells, indicating that this com-
pound is hardly displaced with 100 nM [3H]AVP.
Subsequently, AVP binding was tested on the V2R mutants
treated with the antagonists. Although we observed no BM
localization, but some maturation, for V2R-L44P, -I130F, or
-S167T on treatment with SR4, this compound increased the
number of AVP binding sites 4.2-fold (Fig. 4B). OPC3 and
Fig. 4. Functional rescue of V2R mutants. MDCK II-wt-V2R (A) or
V2R-L44P, -I130F, -S167T, or -S167L (indicated; B) cells were seeded on
filters, grown to confluence followed by 16 h treatment with 1 M of the
indicated pharmacological chaperones or left untreated. Next, cells were
washed with PBS-CM followed by labeling with 100 nM [3H]AVP for 1 h
at 4°C. Filters were washed 3 times with PBS-CM, excised, and counted in
a scintillation counter. Values for untreated samples were set to 1. C:
MDCK II-wt-V2R, MDCK-V2R-L44P, -I130F, -S167T, or -S167L cells
(indicated) were seeded, grown, and treated as described above. Cells were
subsequently washed in PBS-CM and challenged for 10 min with 100 nM
DDAVP in the presence of IBMX. cAMP accumulation was measured
using a fluorescent cAMP assay kit. All experiments were performed at
least in triplicate.
Fig. 3. Effect of DDAVP on MDCK cells expressing wt-V2R or mutants in
NDI. A: MDCK II-wt-V2R, V2R-L44P, -I130F, -S167T, or -S167L (indicated)
were seeded on filters, grown to confluence, washed with ice-cold PBS
containing 1 mM MgCl2 and 0.1 mM CaCl2 (PBS-CM), and subsequently
incubated for 1 h with 100 nM [3H]AVP for 1 h at 4°C to allow radioligand
binding to cell-surface receptors. Subsequently, the filters with the cells were
washed 3 times with ice-cold PBS-CM, excised, and counted in a scintillation
counter. B: MDCK II-wt-V2R, V2R-L44P, -I130F, -S167T, or -S167L (indi-
cated) were seeded on filters, grown to confluence, and subsequently treated
with IBMX alone, or in combination with 100 nM DDAVP on the basolateral
side. Subsequently, cells were lysed and cAMP accumulation was measured
using a fluorescent cAMP assay kit. Triplicate samples were measured, and
experiments were performed at least in triplicate. *Significantly different from
untreated samples (P  0.01).
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OPC4 treatment, which clearly increased V2R mutant BM
localization and maturation, increased the number of binding
sites for these three mutants two- to threefold. In contrast,
despite the clear BM localization and maturation of V2R-
L44P, -I130F, or -S167T on treatment with SR1, incubation
with this drug did not lead to a significant increase in binding
sites for these mutants (P  0.05, n  3; Fig. 4B). No
significantly increased numbers of AVP binding sites were
measured for the nonfunctional mutant V2R-S167L with any
of the treatments (Fig. 4B).
To test whether AVP binding also leads to intracellular
signaling, cAMP measurements were performed following the
same treatments as for the binding experiments. The relative
cAMP levels generated (Fig. 4C) were in line with the obtained
levels of AVP binding (Fig. 4B).
Functional rescue at reduced antagonist and AVP concen-
trations. In line with the choice for the use of a V1R antagonist
in patients (5), our data above suggest that SR4 is most
effective to functionally rescue mutant V2R in patients. How-
ever, the concentrations of the antagonists (1 M) and AVP
(100 nM) used will be difficult to obtain in patients. Therefore,
we tested functional rescue of the V2R mutants at decreased
antagonist concentrations and measured cAMP levels after
stimulation with 0.1–10 nM concentrations of AVP. As shown
in Fig. 5A, pretreatment of V2R-L44P-expressing cells with 1
or 0.1 nM SR4 did not yield a further cAMP response on
stimulation with any of the AVP concentrations used. Pretreat-
ment with 1 or 0.1 nM OPC3 or OPC4, however, led to a two-
to fourfold increase in cAMP levels when cells were stimulated
with 1 or 10 nM AVP, respectively. Similar results were
obtained for V2R-I130F and -S167T (not shown). Pretreatment
with SR1 did not result in significantly increased cAMP levels
(P  0.05) when tested in the conditions above (not shown).
To determine the level of rescued cell surface expression at
lower CPA concentrations, cells expressing V2R-L44P,
-I130F, -S167T were treated for 16 h with 100–3 nM concen-
trations of OPC3, OPC4, or SR1 and immunoblotted (Fig. 5B).
At 100 and 30 nM concentrations, the extent of maturation (75-
vs. 60-kDa signals) of V2R-L44P was highest for SR1 and
OPC4, whereas OPC3 showed only a limited amount (100 nM)
or no (30 nM) mature V2R. A further decrease in the concen-
tration of the CPAns to 10 nM did not reveal any further
maturation but showed an increased V2R-L44P expression for
SR1-treated cells only. This SR1-specific effect on V2R-L44P
expression was also found with 30 and 100 nM concentrations
(Fig. 5B, 2 top panels). Treatment with 3 nM (Fig. 5B, bottom)
of any of the CPAns showed no further effect on V2R-L44P
maturation or expression level. Similar data were found for the
mutants V2R-I130F and -S167T (not shown).
Time-resolved functional rescue of V2R mutants. On admin-
istration to patients, the blood concentrations of the antagonists
will not be stable in time. Therefore, it is important to know
how long it takes for the antagonists to confer a functionally
rescued V2R phenotype, and whether this is different between
antagonists. To study this, cells expressing V2R-L44P, -I130F,
and -S167T were treated at different time points with 0.1 nM
of the pharmacological chaperones, followed by [3H]AVP
labeling to semiquantify the available AVP binding sites at the
cell surface. Treatment of V2R-L44P, -I130F, or -S167T cells
with OPC3 and OPC4 increased the available binding sites up
to threefold, which became apparent after 8 h of treatment and
did not further increase between 8 and 16 h of treatment (Fig.
6). Consistent with the absence of any rescue at the low
concentrations used, SR4 treatment did not significantly (P 
0.05) affect [3H]AVP binding at any of the time points. These
data indicated that in cell culture, between 4 and 8 h of
treatment with a 0.1 nM antagonist is needed for a maximal
functional rescue of the V2R mutants.
DISCUSSION
Pharmacological chaperones rescue a broad spectrum of
V2R mutants. By definition, class II mutant proteins are ER
retained due to misfolding. Binding of an antagonist to a
mutant receptor can reverse the distorting effect of the muta-
tion and thus aid in protein folding (3, 32). Indeed, our study
reveals that all nine V2R mutants in NDI tested, except for
V2R-S167L, are stabilized by the antagonists used, resulting in
different levels of receptor maturation. In line with the finding
of Tan et al. (31) that achieving the proper complex glycosyl-
ation state is necessary for V2R to reach the BM, maturation of
the V2R mutants on immunoblotting coincides with BM ex-
Fig. 5. Concentration-dependent functional rescue of V2R-L44P. MDCK
II-V2R-L44P cells were seeded and grown to confluence, followed by a 16-h
treatment with the indicated concentrations of SR4, OPC3, or OPC4. A: cells
were washed with PBS-CM followed by a 10-min challenge with different
concentrations of AVP (indicated) in the presence of IBMX. Subsequently,
cells were lysed and cAMP accumulation measured using a fluorescent cAMP
assay kit. All experiments were performed at least in triplicate. B: cells were
lysed and subsequently analyzed by SDS-PAGE followed by immunoblotting
using anti-GFP antibodies. Molecular masses (in kDa) are indicated on the left.
All experiments were performed at least in triplicate.
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pression as detected by CLSM. Consistently, V2R-S167L did
not mature with any of the ligands and failed to leave the ER,
which has been suggested to be due to severe distortion of the
structure (34). Our data indicate, however, that V2R-S167L
can be bound by the V2R antagonist SR1, as administration of
this drug increased the amount of immature proteins (Fig. 1). A
similar ER-stabilizing effect has been observed for the non-
peptide antagonist naltrexone on immature forms of the -opi-
oid receptor (21).
In line with the data from Morello et al. (18), the rescue of
multiple V2R mutants reveals the high efficacy by which
nonpeptide antagonists stabilize ER-retained mutant proteins.
These effects were observed for different clones obtained in
MDCK I (not shown) and MDCK II cell lines, indicating that
the effects were inherent to the V2R mutant and not due to
clonal differences. In contrast, using the same V2R mutants, a
subset of chemical chaperones restored the BM localization of
only one mutant, V2R-V206D (26). In addition, the level of
maturation and cell surface rescue of V2R-V206D on treatment
with chemical chaperones was also less than observed for the
antagonists OPC3, OPC4, and SR1 (not shown). This is likely
due to their different modes of action, as cell-permeable
antagonists stabilize the receptor’s conformation through direct
interaction, whereas chemical chaperones may evoke a stress
response, modify the activity of folding proteins, or dehydrate
the mutant’s environment (33).
In general, the extent of cell surface rescue of V2R mutants
is determined by the affinity of the antagonists. Brothers et al.
(6) suggested that COOH-terminal fusion of GFP to a receptor
might induce plasma membrane expression. However, our data
reveal that this is not the case here, as the MDCK cells
expressing the GFP-tagged V2R mutants have no significant
radioligand binding or cAMP signaling after agonist stimula-
tion (Fig. 3). Following rescue to the cell surface, however,
most of the V2R mutants are able to bind AVP and conse-
quently elicit a cAMP response. Our data show that SR1 and
OPC4 induce maturation of V2R-L44P, -I130F, and -S167T
the best, followed by OPC3 and, much less, SR4 (Figs. 1 and
5B). Similarly, at 1 M concentrations, SR1, OPC4, and OPC3
induce a robust cell surface rescue, whereas SR4 induced no
detectable translocation (Fig. 2). A similarly reduced rescue for
V2R-S167T and V2R-62–64 by SR4 compared with SR1
was found by others (34). With the exclusion of severely
distorted receptors (V2R-S167L), our data indicate that the
level of maturation and translocation of V2R mutants in gen-
eral is directly related to the antagonists’ affinities for V2R
(Table 1), as similar relative effects were observed for eight of
nine V2R mutants tested.
Functional rescue is a balance between membrane expres-
sion and displacement by DDAVP. Once at the plasma mem-
brane, functional rescue can only occur if the pharmacological
chaperone is displaced by an agonist, thereby allowing receptor
activation and induction of the signaling cascade (12). Our data
reveal that for functional rescue of V2R mutants, the pharma-
cological chaperone should fit two contradictory criteria: it
should have a sufficient high affinity to facilitate the mutant
receptor’s stabilization and translocation to the plasma mem-
brane, but its binding should not be so strong as to interfere
with its displacement by AVP. Moreover, our data confirm that
the extent of functional rescue critically depends on the con-
centration used (12, 18).
At high concentrations (1 M), SR4 showed a weak cell
surface rescuing effect for the V2R mutants, whereas OPC3,
OPC4, and SR1 rescued large amounts of receptor to the BM
(Figs. 1 and 2). Nevertheless, subsequent AVP binding and
cAMP generation are considerably lower for OPC3-, OPC4-,
and SR1- compared with SR4-treated cells and correlates
largely with their affinities for the V2R (Fig. 4, B and C; Table
1). These data indicated that the extent of displacement by
DDAVP is of major importance at these concentrations. A
better functional rescue is obtained with a few rescued recep-
tors which are fully available for AVP binding (SR4) than
when many V2R mutants are rescued, which are limitedly
available for AVP binding (OPC3, OPC4, SR1). At low con-
centrations, however, pretreatment with (sub)nanomolar con-
centrations of OPC3, OPC4, or SR4, followed by stimulation
with 1–10 nM AVP, only resulted in increased cAMP levels
for OPC3 and OPC4 (Fig. 5). As shown in Fig. 5B, low
concentrations of OPC3 and OPC4 are still able to induce cell
surface trafficking and maturation, whereas SR4 is not. There-
Table 1. Characteristics of pharmacological chaperones
Compound Abbreviation Ki, nM
SR49059 SR4 27550 V1R antagonist
OPC31260 OPC3 9.420.90 V2R antagonist
OPC41061 OPC4 0.430.06 V2R antagonist
SR121463 SR1 0.540.08 V2R antagonist
Values are means  SE. V1R and V2R, V1 and V2 receptor; respectively.
The values of the inhibitory constant (Ki) for OPC3(1260), OPC4(1061),
SR4(9059), and SR1(21463) on the human V2R are as described elsewhere
(28–30, 36).
Fig. 6. Time-resolved rescue of V2R-L44P, -I130F, and -S167T. MDCK
II-V2R-L44P (A), -I130F (B), or -S167T cells (C) were seeded and grown to
confluence and treated for 0, 4, 8, or 16 h with 0.1 nM SR4 (}), OPC3 (■), or
OPC4 (Œ). Subsequently, cells were incubated for 1 h with 1 nM [3H]AVP at
4°C followed by 3 washes with ice-cold PBS-CM, excision of the filters, and
counting in a scintillation counter.
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fore, at low antagonist concentrations, the extent of rescued
cell surface expression becomes critical.
The absence of functional rescue on SR1 treatment seems to
contradict data published by Morello et al. (18), who found that
cAMP levels increased up to 15-fold in V2R mutants pre-
treated with SR1. This difference is most likely due to the
higher agonist/antagonist ratio and concentrations use by Mo-
rello et al., which were 10- and 100-fold higher compared with
our “high concentration amounts,” respectively. This, however,
provides additional support that the observed effect on cAMP
generation depends on the concentrations used and ratios of
antagonist to agonist.
Surprisingly, OPC4 and SR1 have similar affinities for the
V2R (Table 1), but OPC4 was easier displaced by AVP than
SR1 (Fig. 4A) and consequently yielded better functional
rescue at any concentration used (Fig. 4, B and C). This
difference was not caused by a reduced V2R mutant cell
surface expression with SR1, as at low concentrations this was
similar to, or better than, that of OPC4 or OPC3. Possibly, the
different effects observed for SR1 and OPC4 might be due to
differences in their V2R binding sites, as recently established
(15). This is underscored by our finding that SR1, but not
OPC4, stabilizes the ER-retained form of V2R-S167L (Fig. 1).
These data reveal that compound-intrinsic factors other than
their affinities influence their extent of displacement by AVP
and ability to confer functional rescue.
Optimal pharmacological chaperone to treat congenital
NDI. Treatment with SR4 showed a significant increase in
urine concentration in three NDI patients encoding V2R-
R137H, thereby providing proof of the principle that pharma-
cological chaperones can relieve NDI (5). In two other patients
encoding V2R-W164S and 62–64 (185–193del), however,
the response to SR4 treatment was weaker. Interestingly, V2R-
R137H is only a partial class II mutant, as a considerable
portion of this mutant is fully matured but is constitutively
internalized from the plasma membrane (class V) (1), whereas
V2R-W164S and 62–64 are fully retained in the ER (5). The
reduced ER retention suggests a low level of misfolding of
V2R-R137H, and the difference in the extent of ER-retention
between V2R-R137H and other V2R mutants may underlie the
observed effects of SR4 in NDI patients (4). Likely due to its
low maximal blood plasma concentration of 30 nM (D. Bichet,
personal communication), SR4 does not effectively rescue full
class II mutants at low concentrations (Fig. 5A). As OPC3 and
OPC4 allow functional rescue of fully ER-retained V2R mu-
tants at nanomolar concentrations and NDI patients harboring
full class II mutations are much more common (25), these
compounds are anticipated to relieve NDI better than SR4 and
in more NDI patients. Moreover, and in line with the adopted
strategy by Bernier et al. (5), continuously elevated levels of
the antagonists are needed, as it takes 4 h before a functional
rescue is obtained (Fig. 6). Since nonpeptide antagonists re-
main active in vivo up to 8 h (11, 27), this would require the
administration of at least three doses per day. The analyses in
patients will be the subject of future studies.
In conclusion, we have demonstrated that cell-permeable
V2R antagonists can rescue the cell surface expression of a
broad spectrum of ER-retained V2R mutants and that func-
tional rescue is a balance between a cell-permeable antago-
nist’s ability to rescue the cell surface expression of the V2R
mutant and its ability to be displaced by AVP. Moreover, we
show that at low concentrations the functional rescue occurs
most efficiently by antagonists with a relatively high affinity
for the receptor (Fig. 7). Our findings that a large number of
V2R mutants are rescued by pharmacological chaperones and
that functional rescue of mutant V2Rs at low antagonist con-
centrations is most effective with relatively high-affinity an-
tagonists are anticipated to become important for other dis-
eases, such as hypogonadotrophic hypogonadism (12), early-
onset obesity (16), or hypothyroidism (7), in which mutations
in G protein-coupled receptors are causal and for which cell-
permeable antagonists are, or may become, available.
Concerning NDI patients with V2R mutations, of the four
compounds tested, OPC3(1260) and OPC4(1061) combine cell
surface rescue and displacement by AVP best when tested with
low antagonist and near-physiological AVP concentrations.
While other high-affinity V2R antagonists might be as suitable,
OPC31260 is currently being tested as a treatment for poly-
cystic kidney disease (2), while OPC41601 is under trial to
treat hyponatremia and congestive heart failure in humans (19).
Since negative side or toxicity effects have not been reported in
these studies, OPC31260 and OPC41061 represent safe and
promising candidates to treat NDI in patients with type II
mutations in the V2R. (30, 36)
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